Table 1.

Phase II studies incorporating targeted agents in advanced gastroesophageal cancer

Targeted agent	Chemotherapy	N	RR	PFS (months)	OS (months)	Reference
Cetuximab	Irinotecan and FU	49	42%	8.6	16.6	Kanzler et al. [11]
Bevacizumab	Docetaxel, FU and cisplatin	44	67%	12	16.2	Kelsen et al. [12]
Cetuximab	Irinotecan and oxaliplatin	51	60%	6	9.5	Woell et al. [13]

N: patient number; RR: response rate; PFS: progression-free survival; OS: overall survival; FU: 5-fluorouracil